Navigating RCC Progression: Optimizing Treatment Sequence After the First Line

Video content above is prompted by the following:

• In your experience, what patterns of progression are emerging with current frontline regimens for advanced RCC, and are there notable differences between IO/IO and IO/TKI combinations? How do these progression patterns—such as common sites of progression or timing—impact prognosis and influence your choice of subsequent therapy?
• When a patient progresses on frontline therapy, how do you approach treatment selection in the later-line setting?
• Does your choice differ based on whether the patient received IO-IO or IO-TKI in the first line? What clinical and disease-specific factors most influence your decision?